CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 25, 2018--
AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that Michael
Bailey, president and chief executive officer, will present at the
following investor conferences:
2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018
at 4:00 p.m. Eastern Time. The conference is being held at the
Intercontinental New York Barclay Hotel.
Leerink Partners Roundtable Series: Rare Disease & Oncology on
Wednesday, October 3, 2018 at 1:00 p.m. Eastern Time. The conference
is being held at the Lotte New York Palace Hotel.
A live webcast of the presentations can be accessed by visiting the
investors section of the Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
About AVEO Pharmaceuticals, Inc .
AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical
company dedicated to advancing a broad portfolio of targeted medicines
for oncology and other areas of unmet medical need. The Company’s
strategy is to retain North American rights to its oncology portfolio
while securing partners in development and commercialization outside of
North America. The Company is seeking to develop and commercialize its
lead candidate tivozanib in North America as a treatment for advanced
renal cell carcinoma (“RCC”). The Company has outlicensed tivozanib
(FOTIVDA®) for oncology in Europe and other territories outside of North
America. Tivozanib is approved in the European Union, as well as Norway
and Iceland, for the first-line treatment of adult patients with RCC and
for adult patients who are vascular endothelial growth factor receptor
and mTOR pathway inhibitor-naïve following disease progression after one
prior treatment with cytokine therapy for RCC. The Company has entered
into partnerships to fund the development and commercialization of
AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in
oncology. The Company is currently seeking a partner to develop the
AV-353 platform, a preclinical asset, worldwide for the potential
treatment of pulmonary arterial hypertension. The Company has recently
regained the rights to its AV-380 program for the potential treatment of
cachexia and is considering a variety of options to advance the
For more information, please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005295/en/
Source: AVEO Pharmaceuticals, Inc.
David Pitts, 212-600-1902